Mabpharm Limited (HKG:2181)
Hong Kong · Delayed Price · Currency is HKD 0.5100
0.00 (0.00%)
Feb 11, 2026, 3:33 PM HKT
Mabpharm Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 423.93 | 258.23 | 87.16 | 55.92 | 82.88 | - |
| 423.93 | 258.23 | 87.16 | 55.92 | 82.88 | - | |
Revenue Growth (YoY) | 179.59% | 196.27% | 55.87% | -32.53% | - | - |
Cost of Revenue | 57.65 | 38.83 | 11.92 | 15.38 | 16.78 | - |
Gross Profit | 366.28 | 219.39 | 75.24 | 40.54 | 66.11 | - |
Selling, General & Admin | 346.34 | 261.98 | 153.58 | 118.77 | 100.06 | 65.8 |
Research & Development | 42.73 | 75.21 | 123.21 | 147.91 | 263.57 | 120.42 |
Operating Expenses | 390.15 | 339.07 | 277.22 | 266.79 | 363.63 | 186.21 |
Operating Income | -23.87 | -119.67 | -201.98 | -226.25 | -297.52 | -186.21 |
Interest Expense | -10.56 | -10.55 | -9.58 | -7.19 | -2.4 | -3.94 |
Interest & Investment Income | 0.54 | 0.51 | 0.15 | 0.38 | 1.95 | 9.46 |
Currency Exchange Gain (Loss) | -0.69 | -1.2 | -1.37 | -4 | -6.59 | -31.9 |
Other Non Operating Income (Expenses) | 6.93 | 2.69 | 3.08 | 25.92 | 12.89 | 27.97 |
EBT Excluding Unusual Items | -27.64 | -128.22 | -209.7 | -211.14 | -291.67 | -184.63 |
Gain (Loss) on Sale of Investments | 0.01 | 0.12 | 0.34 | 0.04 | - | - |
Gain (Loss) on Sale of Assets | - | - | - | 0.03 | -0.07 | - |
Other Unusual Items | 0.16 | 0.16 | - | 0.24 | - | - |
Pretax Income | -27.48 | -127.95 | -209.36 | -210.82 | -291.74 | -184.63 |
Earnings From Continuing Operations | -27.48 | -127.95 | -209.36 | -210.82 | -291.74 | -184.63 |
Net Income | -27.48 | -127.95 | -209.36 | -210.82 | -291.74 | -184.63 |
Net Income to Common | -27.48 | -127.95 | -209.36 | -210.82 | -291.74 | -184.63 |
Shares Outstanding (Basic) | 4,124 | 4,124 | 4,124 | 4,124 | 4,124 | 4,124 |
Shares Outstanding (Diluted) | 4,124 | 4,124 | 4,124 | 4,124 | 4,124 | 4,124 |
Shares Change (YoY) | - | - | - | - | - | 8.47% |
EPS (Basic) | -0.01 | -0.03 | -0.05 | -0.05 | -0.07 | -0.04 |
EPS (Diluted) | -0.01 | -0.03 | -0.05 | -0.05 | -0.07 | -0.04 |
Free Cash Flow | 53.59 | -30.24 | 38.35 | -182.01 | -348.14 | -344.47 |
Free Cash Flow Per Share | 0.01 | -0.01 | 0.01 | -0.04 | -0.08 | -0.08 |
Gross Margin | 86.40% | 84.96% | 86.32% | 72.50% | 79.76% | - |
Operating Margin | -5.63% | -46.34% | -231.74% | -404.61% | -358.97% | - |
Profit Margin | -6.48% | -49.55% | -240.19% | -377.01% | -352.00% | - |
Free Cash Flow Margin | 12.64% | -11.71% | 44.00% | -325.50% | -420.04% | - |
EBITDA | 30.59 | -65.94 | -150.13 | -183.68 | -262.78 | -169.93 |
EBITDA Margin | 7.22% | -25.54% | -172.24% | - | - | - |
D&A For EBITDA | 54.46 | 53.73 | 51.86 | 42.57 | 34.74 | 16.28 |
EBIT | -23.87 | -119.67 | -201.98 | -226.25 | -297.52 | -186.21 |
EBIT Margin | -5.63% | -46.34% | -231.74% | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.